145 related articles for article (PubMed ID: 37053347)
1. [Investigation of the mutational status of the FGFR3 gene in urothelial bladder carcinoma].
Oliushina EM; Zavalishina LE; Alekseenok EY; Oskina NA; Andreeva YY; Kuznetsova OA; Filipenko ML; Frank GA
Arkh Patol; 2023; 85(2):5-12. PubMed ID: 37053347
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma.
Kim YS; Kim K; Kwon GY; Lee SJ; Park SH
BMC Urol; 2018 Jul; 18(1):68. PubMed ID: 30064409
[TBL] [Abstract][Full Text] [Related]
3. [Predictive markers of immunotherapy in cervical cancer].
Oliushina EM; Zavalishina LE; Andreeva YY; Kuznetsova OA; Moskvina LV; Frank GA
Arkh Patol; 2023; 85(5):5-12. PubMed ID: 37814844
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer.
Wang L; Gong Y; Saci A; Szabo PM; Martini A; Necchi A; Siefker-Radtke A; Pal S; Plimack ER; Sfakianos JP; Bhardwaj N; Horowitz A; Farkas AM; Mulholland D; Fischer BS; Oh WK; Sharma P; Zhu J; Galsky MD
Eur Urol; 2019 Nov; 76(5):599-603. PubMed ID: 31272788
[TBL] [Abstract][Full Text] [Related]
5. FGFR3 Mutational Activation Can Induce Luminal-like Papillary Bladder Tumor Formation and Favors a Male Sex Bias.
Shi MJ; Fontugne J; Moreno-Vega A; Meng XY; Groeneveld C; Dufour F; Kamoun A; Viborg Lindskrog S; Cabel L; Krucker C; Rapinat A; Dunois-Larde C; Lepage ML; Chapeaublanc E; Levrel O; Dixon V; Lebret T; Almeida A; De Reynies A; Rochel N; Dyrskjøt L; Allory Y; Radvanyi F; Bernard-Pierrot I
Eur Urol; 2023 Jan; 83(1):70-81. PubMed ID: 36273937
[TBL] [Abstract][Full Text] [Related]
6. Molecular investigation of FGFR3 gene mutation and its correlation with clinicopathological findings in Indian bladder cancer patients.
Ahmad F; Mahal V; Verma G; Bhatia S; Das BR
Cancer Rep (Hoboken); 2018 Oct; 1(3):e1130. PubMed ID: 32721083
[TBL] [Abstract][Full Text] [Related]
7. HPV-positive clinically advanced squamous cell carcinoma of the urinary bladder (aBSCC): A comprehensive genomic profiling (CGP) study.
Ghelani GH; Zerdan MB; Jacob J; Spiess PE; Li R; Necchi A; Grivas P; Kamat A; Danziger N; Lin D; Huang R; Decker B; Sokol ES; Cheng L; Pavlick D; Ross JS; Bratslavsky G; Basnet A
Urol Oncol; 2023 Dec; 41(12):486.e15-486.e23. PubMed ID: 37821306
[TBL] [Abstract][Full Text] [Related]
8. Status of PD-1 and PD-L1 expression in invasive urothelial carcinoma of the bladder with mismatch repair protein deficiency.
Sungu N; Kıran MM
Pol J Pathol; 2023; 74(3):161-170. PubMed ID: 37955535
[TBL] [Abstract][Full Text] [Related]
9. Analysis of papillary urothelial carcinomas of the bladder with grade heterogeneity: supportive evidence for an early role of CDKN2A deletions in the FGFR3 pathway.
Downes MR; Weening B; van Rhijn BW; Have CL; Treurniet KM; van der Kwast TH
Histopathology; 2017 Jan; 70(2):281-289. PubMed ID: 27530957
[TBL] [Abstract][Full Text] [Related]
10. Frequent Telomerase Reverse Transcriptase Promoter and Fibroblast Growth Factor Receptor 3 Mutations Support the Precursor Nature of Papillary Urothelial Hyperplasia of the Urinary Bladder.
Cheng L; Lopez-Beltran A; Wang M; Whaley RD; De Souza A; Au S; Ge R; Cimadamore A; Amin A; Golijanin B; MacLennan GT; Osunkoya AO; Montironi R; Zhang S
Mod Pathol; 2023 Jul; 36(7):100151. PubMed ID: 36906071
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic and Genomic Characterization of PD-L1 Positive Urothelial Carcinomas.
Huang RSP; Haberberger J; Harries L; Severson E; Duncan DL; Ferguson NL; Hemmerich A; Edgerly C; Murugesan K; Xiao J; McEwan D; Holmes O; Hiemenz M; Venstrom J; Elvin JA; Creeden J; Lin DI; Ross JS; Ramkissoon SH
Oncologist; 2021 May; 26(5):375-382. PubMed ID: 33687775
[TBL] [Abstract][Full Text] [Related]
12. Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients.
Mertens LS; Claps F; Mayr R; Bostrom PJ; Shariat SF; Zwarthoff EC; Boormans JL; Abas C; van Leenders GJLH; Götz S; Hippe K; Bertz S; Neuzillet Y; Sanders J; Broeks A; Peters D; van der Heijden MS; Jewett MAS; Stöhr R; Zlotta AR; Eckstein M; Soorojebally Y; van der Schoot DKE; Wullich B; Burger M; Otto W; Radvanyi F; Sirab N; Pouessel D; van der Kwast TH; Hartmann A; Lotan Y; Allory Y; Zuiverloon TCM; van Rhijn BWG
Urol Oncol; 2022 Mar; 40(3):110.e1-110.e9. PubMed ID: 34906411
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast growth factor receptor 3 gene (FGFR3) mutations in high-grade muscle-invasive urothelial bladder cancer in a Brazilian population: evaluation and prevalence.
Monteiro CRA; Korkes F; Krutman-Zveibil D; Glina S
Einstein (Sao Paulo); 2022; 20():eAO6450. PubMed ID: 35384983
[TBL] [Abstract][Full Text] [Related]
14. Mutations of fibroblast growth factor receptor 3 gene (FGFR3) in transitional cell carcinoma of urinary bladder in Thai patients [Revision-2a].
Jantip J; Tanthanuch M; Kanngurn S; Karnchanawanichkul W; Pripatnanont C; Sangkhathat S; Thongsuksai P
J Med Assoc Thai; 2013 Aug; 96(8):976-83. PubMed ID: 23991606
[TBL] [Abstract][Full Text] [Related]
15. FGFR3 Destabilizes PD-L1 via NEDD4 to Control T-cell-Mediated Bladder Cancer Immune Surveillance.
Jing W; Wang G; Cui Z; Xiong G; Jiang X; Li Y; Li W; Han B; Chen S; Shi B
Cancer Res; 2022 Jan; 82(1):114-129. PubMed ID: 34753771
[TBL] [Abstract][Full Text] [Related]
16. High CDKN2A/p16 and Low FGFR3 Expression Predict Progressive Potential of Stage pT1 Urothelial Bladder Carcinoma.
Breyer J; Wirtz RM; Erben P; Worst TS; Stoehr R; Eckstein M; Bertz S; Sikic D; Denzinger S; Burger M; Hartmann A; Otto W;
Clin Genitourin Cancer; 2018 Aug; 16(4):248-256.e2. PubMed ID: 29525349
[TBL] [Abstract][Full Text] [Related]
17. Transcriptomic Profiling of Upper Tract Urothelial Carcinoma: Bladder Cancer Consensus Classification Relevance, Molecular Heterogeneity, and Differential Immune Signatures.
Fontugne J; Xylinas E; Krucker C; Dixon V; Groeneveld CS; Pinar U; Califano G; Bucau M; Verine J; Desgrandchamps F; Hermieu JF; Radvanyi F; Allory Y; Masson-Lecomte A
Mod Pathol; 2023 Nov; 36(11):100300. PubMed ID: 37558130
[TBL] [Abstract][Full Text] [Related]
18. Expression of p53 Protein Associates with Anti-PD-L1 Treatment Response on Human-Derived Xenograft Model of GATA3/CR5/6-Negative Recurrent Nonmuscular Invasive Bladder Urothelial Carcinoma.
Blinova E; Samishina E; Deryabina O; Blinov D; Roshchin D; Shich E; Tumutolova O; Fedoseykin I; Epishkina A; Barakat H; Kaprin A; Zhandarov K; Perepechin D; Merinov D; Brykin G; Arutiunian K; Serebrianyi S; Mirontsev A; Kozdoba A
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576020
[TBL] [Abstract][Full Text] [Related]
19. FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population.
Bodoor K; Ghabkari A; Jaradat Z; Alkhateeb A; Jaradat S; Al-Ghazo MA; Matalka I; Musleh H; Haddad Y
Cancer Epidemiol; 2010 Dec; 34(6):724-32. PubMed ID: 20542753
[TBL] [Abstract][Full Text] [Related]
20. FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?
van Rhijn BWG; Mertens LS; Mayr R; Bostrom PJ; Real FX; Zwarthoff EC; Boormans JL; Abas C; van Leenders GJLH; Götz S; Hippe K; Bertz S; Neuzillet Y; Sanders J; Broeks A; van der Heijden MS; Jewett MAS; Marquez M; Stoehr R; Zlotta AR; Eckstein M; Soorojebally Y; Roshani H; Burger M; Otto W; Radvanyi F; Sirab N; Pouessel D; Wullich B; van der Kwast TH; Malats N; Hartmann A; Allory Y; Zuiverloon TCM
Eur Urol; 2020 Nov; 78(5):682-687. PubMed ID: 32682615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
